Lyme Disease Patients With Memory Problems
SuspendedNot applicableNCT03500770
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The main purpose of this study is to see if a device known as Transcranial Direct Current Stimulator (tDCS) is helpful in reducing persistent symptoms after Lyme disease treatment. Some of these symptoms include problems with memory, fatigue or pain.
Study details
- Official title
- Transcranial Direct Current Stimulation (tDCS) for Cognitive Deficit, Fatigue and Pain in Patients With Post Treatment Lyme Disease Syndrome
- Conditions
- Lyme Disease
- Interventions
- Device: Transcranial Direct Current Stimulator
- Sponsor
- Spaulding Rehabilitation Hospital
- Start date
- 2019-02-20
- Primary completion
- 2020-12-30
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Fifteen subjects will be selected to take part in this study. All subjects must meet the following criteria: * Inclusion criteria: 1. Age over 18 years, both males and females 2. History of Lyme disease as diagnosed per CDC criteria and/or evidence of Erythema Migrans or diagnosis of Lyme disease as documented in medical record by an experienced health care practitioner. 3. Meet defining criteria of Post Treatment Lyme Disease Syndrome (PTLDS) proposed by Infectious Diseases Society of America (IDSA) 4. Ability to give informed consent as assessed by study physician 5. Willing to participate in 10 tDCS sessions over two week period 6. If on long-term antibiotics or supplements for treatment of Lyme disease must be willing to keep treatment regimen consistent during participation in the study * Exclusion criteria: 1. Evidence of any active Borrelia infection or co-infection such as Babesiois, Anaplasmosis, Erhlichiosis, Ricketsia as assessed by serum serology, such patient will be referred to ID 2. Evidence of current or prior infection by B. Mioymoti or B. hemsii, such patients will be referred to ID 3. Any of the exclusion criteria of Post Treatment Lyme Disease Syndrome (PTLDS) as proposed by Infectious Diseases Society of America (IDSA) 4. History of other chronic inflammatory conditions such as: * Rheumatoid arthritis * Asthma * Autoimmune diseases * Chronic prostatitis * Glomerulonephritis * Celiac disease * Inflammatory bowel disease * Pelvic inflammatory disease * Interstitial cystitis * Vasculitis 5. Existence of major neurologic or psychiatric condition such as epilepsy, severe depression or others 6. Past history of neurosurgery 7. History of significant alcohol or drug abuse during previous 6 months 8. Presence of unstable medical conditions such as uncontrolled diabetes mellitus, cardiac pathology, cancer, kidney insufficiency, acute thrombosis or others 9. Any new medication or dosage changes in the past 60 days interfering with your symptoms related to PTLDS 10. Concurrent use of opioids or narcotics which cause CNS suppression, cognitive or motor slowing 11. Concurrent use of muscle relaxants 12. Concurrent use of anti-epileptics such as Carbamazepine 13. Pregnancy as assessed by urine pregnancy test 14. Contraindication to tDCS such as metal in the head or implanted electronic medical devices.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03500770